公开(公告)号：US20230358751A1

公开(公告)日：2023-11-09

申请号：US18145602

申请日：2022-12-22

Applicant: Board of Regents, The University of Texas System

Inventor： Samir HANASH ,  Jody VYKOUKAL ,  Timothy THOMPSON ,  Johannes Francois FAHRMANN

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N2405/10 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/50

Abstract: Provided are methods and related kits for detection of early stage prostate cancer, and determination of risk of being at risk for progression of prostate cancer.

公开(公告)号：US09804171B2

公开(公告)日：2017-10-31

申请号：US15045146

申请日：2016-02-16

Applicant: Moleculera Labs, Inc. ,  The Board of Regents of the University of Oklahoma ,  National Institutes of Health

Inventor： Phina Madeleine Cunningham ,  Craig David Shimasaki ,  Susan E. Swedo ,  Christine Kirvan

IPC: A61K38/00 ,  G01N33/53 ,  G01N33/68 ,  G01N33/564 ,  G01N33/569

CPC classification number: G01N33/686 ,  G01N33/564 ,  G01N33/56944 ,  G01N33/6854 ,  G01N33/6896 ,  G01N2333/315 ,  G01N2333/726 ,  G01N2333/912 ,  G01N2405/10 ,  G01N2469/20 ,  G01N2800/26 ,  G01N2800/28 ,  G01N2800/30 ,  G01N2800/38

Abstract: The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and/or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium/calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.

公开(公告)号：US20160334409A1

公开(公告)日：2016-11-17

申请号：US15219820

申请日：2016-07-26

Applicant: Agency for Science, Technology and Research ,  Singapore Health Services Pte Ltd.

Inventor： Sai Kiang LIM ,  Kok Hian TAN

IPC: G01N33/68

CPC classification number: G01N33/689 ,  G01N33/5091 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2405/10 ,  G01N2800/32 ,  G01N2800/368 ,  G01N2800/52 ,  G01N2800/7028

Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.

Abstract translation: 我们描述一种监测细胞，组织，器官或生物体状态的方法。 该方法包括为来自细胞，组织，器官或生物体的微粒样品确定一个比例。 该比例是包含GM1神经节苷脂的选择的多肽，其优选结合霍乱毒素B（CTB）（“GM1神经节苷脂微粒多肽”）到包含暴露的磷脂酰丝氨酸的微粒中所选择的多肽，优选结合膜联蛋白V（ “膜联蛋白V微粒多肽”）。 GM1神经节苷脂微粒多肽与膜联蛋白V微粒多肽的比例如此建立可以指示细胞，组织，器官或生物体的状态。

公开(公告)号：US09066929B2

公开(公告)日：2015-06-30

申请号：US14097294

申请日：2013-12-05

Applicant: NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY ,  KYOWA HAKKO KIRIN CO., LTD.

Inventor： Seiji Yano ,  Yusuke Machino ,  Yui Suzuki

IPC: A61K39/395 ,  G01N33/574 ,  A61K45/06 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3084 ,  C07K2317/732 ,  G01N33/57423 ,  G01N2405/10 ,  G01N2500/00

Abstract: The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved by diagnosing and treating GM2 positive mesothelioma patients with a diagnostic agent and a therapeutic agent that comprise an anti-ganglioside GM2 antibody as an active ingredient.

Abstract translation: 本发明涉及使用与神经节苷脂GM2抗原结合的抗体的治疗方法和诊断方法，以及包含与神经节苷脂GM2抗原结合的抗体作为活性成分的治疗剂和诊断剂。 根据本发明，通过用包含抗神经节苷脂GM2抗体作为活性成分的诊断剂和治疗剂诊断和治疗GM2阳性间皮瘤患者，可以改善GM2阳性间皮瘤患者的预后。

公开(公告)号：US20140220003A1

公开(公告)日：2014-08-07

申请号：US14097294

申请日：2013-12-05

Applicant: KYOWA HAKKO KIRIN CO., LTD ,  NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY

Inventor： Seiji YANO ,  Yusuke MACHINO ,  Yui SUZUKI

IPC: A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3084 ,  C07K2317/732 ,  G01N33/57423 ,  G01N2405/10 ,  G01N2500/00

Abstract: The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved by diagnosing and treating GM2 positive mesothelioma patients with a diagnostic agent and a therapeutic agent that comprise an anti-ganglioside GM2 antibody as an active ingredient.

Abstract translation: 本发明涉及使用与神经节苷脂GM2抗原结合的抗体的治疗方法和诊断方法，以及包含与神经节苷脂GM2抗原结合的抗体作为活性成分的治疗剂和诊断剂。 根据本发明，通过用包含抗神经节苷脂GM2抗体作为活性成分的诊断剂和治疗剂诊断和治疗GM2阳性间皮瘤患者，可以改善GM2阳性间皮瘤患者的预后。

公开(公告)号：US20110256147A1

公开(公告)日：2011-10-20

申请号：US13132234

申请日：2009-12-01

Applicant: Mathias Oelke ,  Jonathan Schneck ,  Tonya Webb

Inventor： Mathias Oelke ,  Jonathan Schneck ,  Tonya Webb

IPC: A61K39/395 ,  C12Q1/02 ,  G01N33/53 ,  A61P11/06 ,  A61K31/702 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08 ,  G01N33/566 ,  A61K31/713

CPC classification number: G01N33/92 ,  G01N33/5011 ,  G01N33/505 ,  G01N33/57484 ,  G01N2405/10

Abstract: Methods of diagnosis and treatment of malignant tumors, in particular ovarian tumors, using GD3 and GD3 inhibitors. Also provided are methods of modulating the immune system of a mammal by the administration of a GD3 and GD3 inhibitors.

Abstract translation: 使用GD3和GD3抑制剂诊断和治疗恶性肿瘤，特别是卵巢肿瘤的方法。 还提供了通过施用GD3和GD3抑制剂调节哺乳动物的免疫系统的方法。

公开(公告)号：US07727735B2

公开(公告)日：2010-06-01

申请号：US11541830

申请日：2006-10-02

Applicant: John L Magnani

Inventor： John L Magnani

IPC: G01N33/574

CPC classification number: C07K16/3069 ,  G01N33/57434 ,  G01N2405/10

Abstract: An antigen is shown to be associated with prostate cancer, and is useful for new methods and compositions for diagnosing or treating prostate cancer. This is particularly useful for individuals with prostate cancer who test negative for Prostate Specific Antigen. Additionally, this is useful for distinguishing between benign prostate disease and prostate cancer in a patient diagnosed or presenting with prostate dysfunction.

Abstract translation: 抗原显示与前列腺癌相关，并且可用于诊断或治疗前列腺癌的新方法和组合物。 这对于前列腺特异性抗原阴性的前列腺癌患者特别有用。 另外，这对于在诊断或呈现前列腺功能障碍的患者中区分良性前列腺疾病和前列腺癌是有用的。

公开(公告)号：US20070048809A1

公开(公告)日：2007-03-01

申请号：US11541830

申请日：2006-10-02

Applicant: John Magnani

Inventor： John Magnani

IPC: G01N33/574

CPC classification number: C07K16/3069 ,  G01N33/57434 ,  G01N2405/10

Abstract: An antigen is shown to be associated with prostate cancer, and is useful for new methods and compositions for diagnosing or treating prostate cancer. This is particularly useful for individuals with prostate cancer who test negative for Prostate Specific Antigen. Additionally, this is useful for distinguishing between benign prostate disease and prostate cancer in a patient diagnosed or presenting with prostate dysfunction.

Abstract translation: 抗原显示与前列腺癌相关，并且可用于诊断或治疗前列腺癌的新方法和组合物。 这对于前列腺特异性抗原阴性的前列腺癌患者特别有用。 另外，这对于在诊断或呈现前列腺功能障碍的患者中区分良性前列腺疾病和前列腺癌是有用的。

公开(公告)号：US07135301B2

公开(公告)日：2006-11-14

申请号：US10176960

申请日：2002-06-21

Applicant: John L. Magnani

Inventor： John L. Magnani

IPC: G01N33/574 ,  C07K16/30

CPC classification number: C07K16/3069 ,  G01N33/57434 ,  G01N2405/10

Abstract: An antigen is shown to be associated with prostate cancer, and is useful for new methods and compositions for diagnosing or treating prostate cancer. This is particularly useful for individuals with prostate cancer who test negative for Prostate Specific Antigen. Additionally, this is useful for distinguishing between benign prostate disease and prostate cancer in a patient diagnosed or presenting with prostate dysfunction.

公开(公告)号：US20060159652A1

公开(公告)日：2006-07-20

申请号：US10528542

申请日：2003-09-19

Applicant: Martin Gagnon ,  H Saragovi

Inventor： Martin Gagnon ,  H Saragovi

IPC: A61K38/19 ,  A61K38/10 ,  C07K7/08

CPC classification number: A61K38/1709 ,  C07K14/78 ,  G01N2405/10 ,  G01N2500/02

Abstract: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.

Abstract translation: 本发明提供神经节苷脂GD2的配体，包括肽配体如GGITNYNSALM; YCGGITNYNSACY; YCITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVCY; GGIANYNTS; YCGGIANYNCY; YCGGIANYNTSCY; 和YCIANYNTCY。 本发明的GD2配体可以例如用于治疗或诊断疾病，例如细胞表达GD2的癌症，包括神经母细胞瘤。